Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 841

Results For "C"

9109 News Found

Margins impacted by high expenses for Pfizer: ICICI Securities
News | May 31, 2021

Margins impacted by high expenses for Pfizer: ICICI Securities

Adjusted PAT declined 18.8% YoY


Cadila Healthcare’s margin supported by lower R&D : ICICI Securities
Drug Approval | May 31, 2021

Cadila Healthcare’s margin supported by lower R&D : ICICI Securities

India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact


Sun Pharmaceutical’s internals remain strong: ICICI Securities
News | May 31, 2021

Sun Pharmaceutical’s internals remain strong: ICICI Securities

US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio


Multiple catalysts ahead for Cadila Healthcare: HDFC Securities
News | May 31, 2021

Multiple catalysts ahead for Cadila Healthcare: HDFC Securities

Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.


Aurobindo Pharma Q4FY21 consolidated net profit at Rs. 801.58 Cr
News | May 31, 2021

Aurobindo Pharma Q4FY21 consolidated net profit at Rs. 801.58 Cr

The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021


IPCA Q4FY21 consolidated net profit slides QoQ to Rs. 161.34 Cr
News | May 29, 2021

IPCA Q4FY21 consolidated net profit slides QoQ to Rs. 161.34 Cr

The company has posted net profit of Rs.1140.01 crores during FY 2020-21


Zydus new initiative to safeguard patients against counterfeit drugs
News | May 29, 2021

Zydus new initiative to safeguard patients against counterfeit drugs

The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website


Shilpa Medicare Jadcherla facility gets GMP certification from Russia
Policy | May 29, 2021

Shilpa Medicare Jadcherla facility gets GMP certification from Russia

The GMP certificate is valid for three years until April 2024.


SMS Pharmaceuticals posts Q4FY21 consolidated PAT of Rs. 22.21 Cr
News | May 29, 2021

SMS Pharmaceuticals posts Q4FY21 consolidated PAT of Rs. 22.21 Cr

It posted net profit of Rs.60.96 crores for the 12 months period ended March 31, 2021


Zydus Cadila's COVID Vaccine in advance stage of trial; Q4 FY21 income up 3%
News | May 28, 2021

Zydus Cadila's COVID Vaccine in advance stage of trial; Q4 FY21 income up 3%

The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year